Search Results 1401-1410 of 19446 for Hemoglobin

1. A Study Using the New TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients with Metastatic, Persistent, Recurrent, or Progressive Solid Tumors - Mayo Clinic

   Hemoglobin >= 10 g/dL; Total bilirubin =< 1.5 X upper limit of normal (ULN) unless history of Gilbert's syndrome documented prior to first-line treatment of ...

2. Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer - Mayo Clinic

   Hemoglobin ≥ 9 g/dL (pre-registration cycle). Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (pre-registration cycle). Aspartate aminotransferase ...

3. A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer - Mayo Clinic

   Hemoglobin ≥9 g/dL,; Platelet count ≥100 x 109/L,; Serum creatinine ≤1.5 x upper limit of normal (ULN) or a calculated creatinine clearance >60 mL/min ...

4. A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL independent of transfusion and/or growth factors within 3 months prior to randomization;; Serum albumin ≥ 3.0 g/dL. Exclusion ...

5. Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma - Mayo Clinic

   Obtained =< 14 days prior to registration: Hemoglobin >= 8.0 g/dL; Obtained =< 14 days prior to registration: Total bilirubin =< 1.5 x upper limit of normal ...

6. Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment - Mayo Clinic

   - Hemoglobin ≥ 10 g/dL. - Total bilirubin ≤ 2 x institutional upper limit of normal (ULN). - Aspartate aminotransferase (AST) serum glutamic oxaloacetic ...

7. A Study To Assess The Feasibility And Safety Of Intratumoral Diffusing Alpha Emitters For The Treatment Of Recurrent Glioblastoma - Mayo Clinic

   ... Hemoglobin (Hgb) ≥ 9 g/dL. Patients must have the following blood chemistry levels at initial screening obtained ≤ 14 days prior to starting treatment AST ...

8. Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery - Mayo Clinic

   Hemoglobin (Hgb) ≥ 9.0 g/dL obtained ≤ 7 days prior to registration; International normalized ratio (INR) and partial thromboplastin (PTT) ≤ 3.0 x ULN ...

9. Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma - Mayo Clinic

   Hemoglobin ≥ 9 g/dL, without transfusion support within 7 days preceding the lab assessment (obtained ≤ 14 days prior to registration). Activated partial ...

10. A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL. Calculated (Calc.) creatinine clearance ≥ 30 mL/min (per Cockcroft-Gault). Total bilirubin ≤ 1.5 x upper limit of normal (ULN) ...